FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk

A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S. market.
Source

Please follow and like us:
Facebook
Facebook
TWITTER
Visit Us
INSTAGRAM

Leave a Comment